Alan D Borthwick

Title: Alan D Borthwick: Innovator in Therapeutic Compounds

Introduction

Alan D Borthwick is a prominent inventor based in London, GB, known for his significant contributions to the field of therapeutic compounds. With an impressive portfolio of 31 patents, he has made strides in medical research, particularly concerning neurological treatments.

Latest Patents

Among his latest inventions, Alan holds patents for crystalline forms of 4-(5-(4,7-dimethylbenzofuran-2-yl)-1,2,4-oxadiazol-3-yl)benzoic acid, commonly referred to as 'BHBA-001'. This invention focuses on the development of selective retinoic acid receptor beta (RARβ) agonists. It includes pharmaceutical compositions aimed at activating RARβ, promoting neurite development, neurite outgrowth, and regeneration, proving beneficial in treating neurological injuries like spinal cord injuries. He is also credited with inventing bicycloheteroaryl-heteroaryl-benzoic acid compounds as retinoic acid receptor beta agonists, which hold therapeutic potential for similar conditions.

Career Highlights

Alan's career includes significant positions at prestigious organizations such as Glaxo Group Limited and King's College London, where he has been instrumental in pioneering research that bridges the gap between laboratory studies and clinical applications.

Collaborations

Through his career, Alan has collaborated with esteemed professionals, including Andrew McMurtrie Mason and Deirdre Mary Bernadette Hickey. These collaborations have further enriched his research and contributed to the advancement of therapeutic innovations.

Conclusion

Alan D Borthwick exemplifies the spirit of innovation in the realm of therapeutic compounds. His work on RARβ agonists not only highlights his expertise but also opens new avenues for the treatment of challenging neurological conditions. His array of patents is a testament to his dedication and knowledge within the field.